Top ▲

Interleukin-2 receptor subunit α

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 1695

Nomenclature: Interleukin-2 receptor subunit α

Family: IL-2 receptor family

Quaternary Structure: Complexes
Interleukin-2 receptor
Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 272 10p15.1 IL2RA interleukin 2 receptor subunit alpha
Mouse 1 268 2 8.91 cM Il2ra interleukin 2 receptor, alpha chain
Rat 1 267 17q12.2 Il2ra interleukin 2 receptor subunit alpha
Previous and Unofficial Names Click here for help
CD25 | TAC antigen | IL2RAC | IL-2R alpha chain | Ly-43 | interleukin 2 receptor
Database Links Click here for help
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
daclizumab Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding >8.0 pKd 1
pKd >8.0 (Kd <1x10-8 M) [1]
basiliximab Peptide Approved drug Immunopharmacology Ligand Hs Binding - -
Immunopharmacology Comments
IL2RA is a ligand binding component of the IL-2R complex. This subunit is the molecular target of the approved biologics daclizumab (including daclizumab beta) and basiliximab. Another anti-CD25 mAb, inolimomab, has received orphan drug designation from the EMA, for the treatment of graft-versus-host disease. Phase 3 findings for this drug and indication are reported in [2], the major conclusion being that the primary end point for the trial was not met (no statistical difference between the inolimomab and normal standard of care arms of the study).
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Immune regulation
Immuno Process:  Immune system development
Immuno Process:  Cytokine production & signalling
Immuno Process:  T cell (activation)
Immuno Process:  Chemotaxis & migration
Immuno Process:  Cellular signalling


Show »

1. Queen CL, Schneider WP, Selick HE. (1997) Genetic engineering; complementarity zones. Patent number: US5693761. Assignee: Protein Design Labs, Inc.. Priority date: 28/12/1988. Publication date: 02/12/1997.

2. Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P et al.. (2017) A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood, 129 (5): 643-649. [PMID:27899357]

How to cite this page

IL-2 receptor family: Interleukin-2 receptor subunit α. Last modified on 27/10/2017. Accessed on 17/06/2024. IUPHAR/BPS Guide to PHARMACOLOGY,